Polaryx Therapeutics appointed Will Charlton as chief medical officer effective September 1, 2026. The role matters to investors because Charlton is expected to lead clinical execution ahead of the company’s planned SOTERIA trial initiation in the fourth quarter of 2026, including development of PLX-200 for rare pediatric disorders.
Key Highlights
- Will Charlton brings experience in pediatric endocrinology, rare disease and clinical development.
- Charlton previously held senior roles at Tyra Biosciences, Spruce Biosciences and 89bio.
- Charlton is Polaryx Therapeutics, Inc.’s chief medical officer.
The appointment comes ahead of Polaryx Therapeutics, Inc. (NASDAQ: PLYX)’s planned SOTERIA trial initiation in the fourth quarter of 2026, with Charlton set to lead clinical execution and advance key milestones.
Charlton Takes Charge of Rare-Disease Development
He spent over a decade in clinical practice and has held senior clinical development and chief medical officer positions across biotechnology companies. At Tyra Biosciences, Charlton served as senior vice president of clinical development for skeletal dysplasia between 2025 and 2026. Earlier, at 89bio between 2020 and 2022, he led clinical development for pegozafermin in MASH and severe hypertriglyceridemia. For the CLN2 and CLN3 cohorts, natural-history data will be used for comparisons with treated patients.
FAQs
Q: Who is Polaryx Therapeutics’ new chief medical officer?
A: Charlton is Polaryx Therapeutics, Inc.’s chief medical officer. He has more than a decade of clinical practice experience and has held senior clinical development and chief medical officer positions across biotechnology companies.
Q: What is Will Charlton expected to lead at Polaryx?
A: Charlton is expected to guide clinical execution for the SOTERIA trial and help advance PLX-200’s development. Polaryx plans to initiate SOTERIA in the fourth quarter of 2026.
Q: What diseases will the SOTERIA trial study?
A: The SOTERIA trial will study CLN2 and CLN3 cohorts. Natural-history data will be used for comparisons with treated patients in both cohorts.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.